Karen Krasney, who serves as Executive Vice President and General Counsel at Capricor Therapeutics (NASDAQ: CAPR), sold 25,000 shares of the company's common stock on March 31, 2026. The transaction was executed at a weighted average price of $30.1174 per share, generating a total proceeds amounting to $752,935. Reported sale prices for the shares ranged between $30.00 and $30.31.
On the same date, Krasney also exercised options to obtain an additional 25,000 shares of Capricor common stock. The stock options were exercised at strike prices of $1.39, $3.18 and $3.74, representing a combined exercise cost of $90,292.
The sales were made under a pre-arranged 10b5-1 trading plan that Krasney adopted in December 2025. After completing the March 31 transactions, Krasney directly holds 30,547 shares of Capricor stock.
At the time of the transaction the market price was trading near $30.06. Capricor's shares have experienced substantial appreciation recently, with a 209% gain over the past 12 months and a 278% rise in the previous six months.
Separately, an InvestingPro analysis cited in company commentary indicates that the stock appears undervalued at current market levels and that analysts are forecasting a return to profitability this year following recent losses. The analysis and additional valuation metrics, including Fair Value assessments and financial health scores, are available in a Pro Research Report on InvestingPro.
In corporate results, Capricor disclosed its fourth-quarter fiscal 2025 earnings, reporting an earnings per share (EPS) loss of -0.62. That outcome missed the consensus estimate of -0.51 and represented a negative surprise of 21.57%. Despite the quarterly shortfall, Cantor Fitzgerald maintained an Overweight rating on the stock and kept its price target at $62.00.
Operationally, the company highlighted an upcoming regulatory milestone: a PDUFA date set for August 22, 2026 for deramiocel, a cardiosphere-derived cell therapy intended to treat Duchenne muscular dystrophy. Capricor also shared new HOPE-3 study data at the Muscular Dystrophy Association, developments that analysts noted as part of the company’s ongoing clinical strategy.
Clear summary
Krasney sold 25,000 Capricor shares on March 31, 2026 for approximately $752,935 and concurrently exercised options to acquire 25,000 shares at a total exercise cost of $90,292. The trades were executed under a 10b5-1 plan adopted in December 2025. Capricor reported a Q4 fiscal 2025 EPS of -0.62, missed estimates, and is preparing for an August 22, 2026 PDUFA date for deramiocel.